Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 2/20 | 0.43 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL911447 | 1.00 | SLC6A2 (0.53) | SLC6A2SLC6A3SLC6A4OPRK1CHRM1 | |
| SCHEMBL3976538 | 1.00 | SLC6A2 (0.53) | SLC6A2SLC6A3SLC6A4OPRK1CHRM1 | |
| SCHEMBL1177691 | 0.94 | SLC6A2 (0.59) | SLC6A2SLC6A3SLC6A4OPRK1CHRM1 | |
| SCHEMBL1177951 | 0.94 | SLC6A2 (0.59) | SLC6A2SLC6A3SLC6A4OPRK1CHRM1 | |
| SCHEMBL1177689 | 0.94 | SLC6A2 (0.59) | SLC6A2SLC6A3SLC6A4OPRK1CHRM1 | |
| SCHEMBL3975583 | 0.87 | SLC6A3 (0.49) | SLC6A2SLC6A3SLC6A4OPRK1CHRM1 | |
| SCHEMBL3975578 | 0.87 | SLC6A3 (0.49) | SLC6A2SLC6A3SLC6A4OPRK1CHRM1 | |
| Fumaric Acid SCHEMBL1177615 | 0.83 | OPRK1 (0.52) | SLC6A2SLC6A3SLC6A4OPRK1HRH1 | |
| SCHEMBL1177378 | 0.82 | SLC6A3 (0.56) | SLC6A2SLC6A3SLC6A4OPRK1DRD3 | |
| SCHEMBL1177377 | 0.82 | SLC6A3 (0.56) | SLC6A2SLC6A3SLC6A4OPRK1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524958-B2 | Certain 9-aza-bicyclo[3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2009-04-28 | — | — | US | claimed |
| US-20070232641-A1 | Novel 9-Aza-Bicyclo[3.3.1]Nonane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | US | claimed |
| EP-1761527-A1 | NOVEL 9-AZA-BICYCLO¬3.3.1|NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-03-14 | — | — | EP | claimed |
| WO-2005123728-A1 | NOVEL 9-AZA-BICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| US-7868017-B2 | 9-azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2011-01-11 | — | — | US | disclosed |
| US-7524958-B2 | Certain 9-aza-bicyclo[3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2009-04-28 | — | — | US | disclosed |
| US-20070232641-A1 | Novel 9-Aza-Bicyclo[3.3.1]Nonane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | NEUROSEARCH A/S (DK) | 2007-10-04 | — | — | US | disclosed |
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | N.V. ORGANON (NL) | 2007-05-17 | — | — | US | disclosed |
| EP-1761527-A1 | NOVEL 9-AZA-BICYCLO¬3.3.1|NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123728-A1 | NOVEL 9-AZA-BICYCLO[3.3.1]NONANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232641-A1 | Novel 9-Aza-Bicyclo[3.3.1]Nonane Derivatives and Their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885SLC6A3 4/4885SLC6A4 6/4885 |
| US-20070112019-A1 | 9-Azabicyclo[3.3.1]nonane derivatives | AZI2, TPMT, TET3 | SLC6A2 1059/4885SLC6A3 339/4885SLC6A4 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.